Asian race and origin have no clinically meaningful effects on polatuzumab vedotin pharmacokinetics in patients with relapsed/refractory B-cell non-Hodgkin lymphoma

PURPOSE: The CD79b-targeted antibody–drug conjugate polatuzumab vedotin (pola), alone and with chemoimmunotherapy, has clinical efficacy and a tolerable safety profile in B-cell non-Hodgkin lymphoma (B-NHL). We assessed (a) whether exposure from global studies of pola is comparable to Asian patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Rong, Lu, Tong, Ku, Grace, Ding, Hao, Saito, Tomohisa, Gibiansky, Leonid, Agarwal, Priya, Li, Xiaobin, Jin, Jin Yan, Girish, Sandhya, Miles, Dale, Li, Chunze, Lu, Dan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7478950/
https://www.ncbi.nlm.nih.gov/pubmed/32770353
http://dx.doi.org/10.1007/s00280-020-04119-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7478950/
https://www.ncbi.nlm.nih.gov/pubmed/32770353
http://dx.doi.org/10.1007/s00280-020-04119-8

Ejemplares similares